Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

NYU Langone establishes new LVAD Program for patients with advanced heart failure

The Cardiac & Vascular Institute at NYU Langone Medical Center has established its new LVAD Program. This surgical intervention program offers eligible, advanced heart failure patients implantation of the latest, lifesaving tool - a left ventricular assist device.

2 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patient has been dosed in its open-label phase IIa trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis of the shoulder, also known as Frozen Shoulder syndrome.

1 Dec 2011

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.

1 Dec 2011

Study reveals no clear advantage of one implant type over another

More than 270,000 Americans get hip replacement surgeries every year -- a number that is projected to double in the next decade as the population ages. With various options for implants, including metal-on-polyethylene, metal-on-metal and ceramic-on-ceramic, there have been questions about which kind works best.

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Ariz. hospitals file suit to stop cuts in Medicaid reimbursements

Arizona hospitals on Tuesday filed suit to block a 5 percent reduction in the rates they're paid to care for Medicaid patients. The suit, filed in U.S. District Court in Phoenix, argues that the rate cut will reduce patient access to health-care providers, in violation of federal law.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

New gene therapy approach safe for patients with muscular dystrophy

Researchers at the University of North Carolina at Chapel Hill have shown that it is safe to cut and paste together different viruses in an effort to create the ultimate vehicle for gene therapy. In a phase I clinical trial, the investigators found no side effects from using a "chimeric" virus to deliver replacement genes for an essential muscle protein in patients with muscular dystrophy.

1 Dec 2011

Potential test to diagnose membranous nephropathy in early stages

Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults.

29 Nov 2011

Most autoimmune diseases associated with increased risk of blood clots on the lung

Autoimmune diseases, in which the immune system attacks the body, are fairly common. Thyroid diseases, type 1 diabetes, rheumatoid arthritis, psoriasis and inflammatory bowel disease are some examples. Autoimmune diseases are associated with increased inflammation in the tissue, which in some cases is linked to an increased propensity to develop clots in the veins.

29 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

BUSM professor receives 2011 ACN Communication Media Award

Michael F. Holick, PhD, MD, director of the General Clinical Research Unit and professor of medicine, physiology and biophysics at Boston University School of Medicine (BUSM) was selected by the American College of Nutrition (ACN) Awards Committee as the 2011 recipient of the ACN Communication Media Award.

23 Nov 2011

CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients

The CIC microGUNE research centre and the Biodonostia Institute have recently started testing a new technique for assessing the severity of inflammatory intestinal diseases, such as Crohn's Disease, in patients at the Donostia Hospital.

23 Nov 2011

Dendritic cells play a novel protective role in pancreas

NYU Langone Medical Center researchers have discovered the novel protective role dendritic cells play in the pancreas. The new study, published in the November issue of journal Gastroenterology, shows dendritic cells can safeguard the pancreas against acute pancreatitis, a sudden dangerous swelling and inflammation of the pancreas gland.

23 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

NYU Langone establishes new LVAD Program for patients with advanced heart failure

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

Study reveals no clear advantage of one implant type over another

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Ariz. hospitals file suit to stop cuts in Medicaid reimbursements

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

New gene therapy approach safe for patients with muscular dystrophy

Potential test to diagnose membranous nephropathy in early stages

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Most autoimmune diseases associated with increased risk of blood clots on the lung

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

BUSM professor receives 2011 ACN Communication Media Award

CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients

Dendritic cells play a novel protective role in pancreas

FDA accepts Regeneron's ARCALYST sBLA for review

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in